CONCLUSIONS: Gentamicin ototoxicity presents with gait imbalance and oscillopsia, but only rarely with hearing loss and vertigo. Sinusoidal rotational stimuli with high accelerations such as the bedside head-thrust test or rotational step changes in velocity are useful to diagnose bilateral vestibulopathy. OBJECTIVE: To describe the salient clinical features and vestibular testing results in gentamicin ototoxicity. PATIENTS AND METHODS: A retrospective review of the quantitative vestibular function testing results for patients presenting to the UCLA Neurotology Clinic with gentamicin ototoxicity over the past 10 years (n=35). RESULTS: All patients presented with imbalance and 33 out of 35 had oscillopsia. Three patients reported a noticeable change in hearing and five reported vertigo. Of the 35 patients, 15 were in renal failure at the time of gentamicin administration. Patients with pre-existing peripheral neuropathy compensated poorly. Sinusoidal rotational testing demonstrated profoundly decreased gain and increased phase lead over the entire frequency range, with a subset of patients having relatively preserved gain at the intermediate frequencies (0.8-1.6 Hz) and low acceleration (<30 degrees/s). There was little or no response to high acceleration step changes in velocity. The time constant measured both by sinusoidal and step responses was ultra-low. All patients tested had a positive head-thrust test bilaterally.
CONCLUSIONS:Gentamicinototoxicity presents with gait imbalance and oscillopsia, but only rarely with hearing loss and vertigo. Sinusoidal rotational stimuli with high accelerations such as the bedside head-thrust test or rotational step changes in velocity are useful to diagnose bilateral vestibulopathy. OBJECTIVE: To describe the salient clinical features and vestibular testing results in gentamicinototoxicity. PATIENTS AND METHODS: A retrospective review of the quantitative vestibular function testing results for patients presenting to the UCLA Neurotology Clinic with gentamicinototoxicity over the past 10 years (n=35). RESULTS: All patients presented with imbalance and 33 out of 35 had oscillopsia. Three patients reported a noticeable change in hearing and five reported vertigo. Of the 35 patients, 15 were in renal failure at the time of gentamicin administration. Patients with pre-existing peripheral neuropathy compensated poorly. Sinusoidal rotational testing demonstrated profoundly decreased gain and increased phase lead over the entire frequency range, with a subset of patients having relatively preserved gain at the intermediate frequencies (0.8-1.6 Hz) and low acceleration (<30 degrees/s). There was little or no response to high acceleration step changes in velocity. The time constant measured both by sinusoidal and step responses was ultra-low. All patients tested had a positive head-thrust test bilaterally.
Authors: Angela C Garinis; Gayla L Poling; Ronald C Rubenstein; Dawn Konrad-Martin; Timothy E Hullar; David M Baguley; Holly L Burrows; Jennifer A Chisholm; Amy Custer; Laura Dreisbach Hawe; Lisa L Hunter; Theodore K Marras; Candice E Ortiz; Lucretia Petersen; Peter S Steyger; Kevin Winthrop; Erika M Zettner; Khaya Clark; Michelle Hungerford; Jay J Vachhani; Carmen C Brewer Journal: Am J Audiol Date: 2021-09-22 Impact factor: 1.636
Authors: Emma J Kenyon; Nerissa K Kirkwood; Siân R Kitcher; Richard J Goodyear; Marco Derudas; Daire M Cantillon; Sarah Baxendale; Antonio de la Vega de León; Virginia N Mahieu; Richard T Osgood; Charlotte Donald Wilson; James C Bull; Simon J Waddell; Tanya T Whitfield; Simon E Ward; Corné J Kros; Guy P Richardson Journal: JCI Insight Date: 2021-04-08
Authors: Florence Lucieer; Stijn Duijn; Vincent Van Rompaey; Angelica Pérez Fornos; Nils Guinand; Jean Philippe Guyot; Herman Kingma; Raymond van de Berg Journal: Front Neurol Date: 2018-06-04 Impact factor: 4.003
Authors: Sofía Ferreira-Cendon; Ramon Martinez-Carranza; Maria José Fernandez-Nava; Rosana Villaoslada-Fuente; Hortensia Sanchez-Gomez; Santiago Santa Cruz-Ruiz; María Sanchez-Ledesma; Angel Batuecas-Caletrio Journal: J Clin Med Date: 2022-01-25 Impact factor: 4.241